Application of thermally responsive elastin-like polypeptide fused to a lactoferrin-derived peptide for treatment of pancreatic cancer

Molecules

Volumn 14, Issue 6, 2009, Pages 1999-2015

  Massodi, Iqbal ^a   Thomas, Emily ^a   Raucher, Drazen ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Drug delivery; Elastin like polypeptide; Hyperthermia; L12; Pancreatic cancer; Thermal targeting

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG CARRIER; LACTATE DEHYDROGENASE; LACTOFERRIN; PEPTIDE;

ANIMAL; ARTICLE; CATTLE; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECT; HEMOLYSIS; HUMAN; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; PANCREAS TUMOR; RAT; SYNTHESIS; TEMPERATURE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CATTLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG CARRIERS; HEMOLYSIS; HUMANS; L-LACTATE DEHYDROGENASE; LACTOFERRIN; MEMBRANE POTENTIAL, MITOCHONDRIAL; PANCREATIC NEOPLASMS; PEPTIDES; RATS; TEMPERATURE;

EID: 67649834226     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules14061999     Document Type: Article

References (46)

1. Allen, T.M. Liposomal drug formulation: rationale for development and what we can expect in the future. Drugs 1998, 56, 747-756.
2. El-Aneed, A. An overview of current delivery systems in cancer gene therapy. J. Control. Release 2004, 94, 1-14.
3. Torchilin, V.P. Polymer-coated long-circulating microparticulate pharmaceuticals. J. Microencapsul. 1998, 75, 1-19.
4. Langer, R. Drug delivery and targeting. Nature (Lond.) 1998, 392 (Suppl.), 5-10.
5. Duncan, R.; Vicent, M.J.; Greco, F.; Nicholson, R.I. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocr. Relat. Cancer 2005, 72 Suppl.7, S189-S99.
6. Kopecek, J.; Kopeckova, P.; Minko, T.; Lu, Z. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm. 2000, 50, 61-81.
7. Takakura, Y.; Fujita, T.; Hashida, M.; Sezaki, H. Disposition characteristics of macromolecules in tumor-bearing mice. Pharm. Res. 1990, 7, 339-346.
8. Maeda, H.; Seymour, L.W.; Miyamoto, Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug. Chem. 1992, 3, 351-362.
9. Cassidy, J.; Duncan, R.; Morrison, G.J.; Strohalm, J.; Plocova, D.; Kopecek, J.; Kaye, S.B. Activity of N-(2-hydroxypropyl)methacrylamide copolymers containing daunomycin against a rat tumour model. Biochem. Pharmacol. 1989, 38, 875-879.
10. Yamaoka, T.; Tabata, Y.; Ikada, Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm. Sci 1994, 83, 601-606.
11. Bidwell, G.L.; Fokt, I.; Priebe, W.; Raucher, D. Development of elastin-like polypeptide for thermally targeted delivery of doxorubicin. Biochem. Pharmacol. 2007, 73, 620-631.
12. Meyer, D.E.; Kong, G.A.; Dewhirst, M.W.; Zalutsky, M.R.; Chilkoti, A. Targeting a Genetically Engineered Elastin-like Polypeptide to Solid Tumors by Local Hyperthermia. Cancer Res. 2001, 67, 1548-1554.
13. Yang, N.; Stensen, W.; Svendsen, J.S.; Rekdal, O. Enhanced antitumor activity and selectivity of lactoferrin-derived peptides. J. Pept. Res. 2002, 60, 187-197.
14. Yang, N.; Strom, M.B.; Mekonnen, S.M.; Svendsen, J.S.; Rekdal, O. The effects of shortening lactoferrin derived peptides against tumour cells, bacteria and normal human cells. J. Pept. Sci. 2004, 70, 37-46.
15. Mader, J.S.; Richardson, A.; Salsman, J.; Top, D.; de Antueno, R.; Duncan, R.; Hoskin, D.W. Bovine lactoferricin causes apoptosis in Jurkat T-leukemia cells by sequential permeabilization of the cell membrane and targeting of mitochondria. Exp. Cell Res. 2007, 373, 2634-2650.
16. Mader, J.S.; Salsman, J.; Conrad, D.M.; Hoskin, D.W. Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines. Mol. Cancer Ther. 2005, 4, 612-624.
17. Eliassen, L.T.; Berge, G.; Leknessund, A.; Wikman, M.; Lindin, I.; Lokke, C.; Ponthan, F.; Johnsen, J.I.; Sveinbjornsson, B.; Kogner, P.; Flaegstad, T.; Rekdal, O. The antimicrobial peptide, lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo. Int. J. Cancer 2006, 779, 493-500.
18. Yoo, Y.C.; Watanabe, R.; Koike, Y.; Mitobe, M.; Shimazaki, K.; Watanabe, S.; Azuma, I. Apoptosis in human leukemic cells induced by lactoferricin, a bovine milk protein-derived peptide: involvement of reactive oxygen species. Biochem. Biophys. Res. Commun. 1997, 237, 624-628.
19. Yoo, Y. C.; Watanabe, S.; Watanabe, R.; Hata, K.; Shimazaki, K.; Azuma, I. Bovine lactoferrin and Lactoferricin inhibit tumor metastasis in mice. Adv. Exp. Med. Biol. 1998, 443, 285-291.
20. Onishi, J.; Roy, M.K.; Juneja, LR.; Watanabe, Y.; Tamai, Y. A lactoferrin-derived peptide with cationic residues concentrated in a region of its helical structure induces necrotic cell death in a leukemic cell line (HL-60). J. Pept. Sci. 2008, 74, 1032-1038.
21. Snyder, E.L.; Dowdy, S.F. Cell penetrating peptides in drug delivery. Pharm. Res. 2004, 27, 389-393.
22. Liu, W.; Dreher, M.R.; Furgeson, D.Y.; Peixoto, K.V.; Yuan, H.; Zalutsky, M.R.; Chilkoti, A. Tumor accumulation, degradation and pharmacokinetics of elastin-like polypeptides in nude mice. J. Control. Release 2006, 776, 170-178.
23. Tatham, A.S.; Shewry, P.R. Elastomeric proteins: biological roles, structures and mechanisms. Trends Biochem. Sci. 2000, 25, 567-571.
24. Urry, D.W.; Luan, C.-H.; Parker, T.M.; Gowda, D.C.; Prasad, K.U.; Reid, M.C.; Safavy, A. Temperature of Polypeptide Inverse Temperature Transition Depends on Mean Residue Hydrophobicity. J. Am. Chem. Soc. 1991, 773, 4346-4348.
25. Fujiwara, K.; Watanabe, T. Effects of hyperthermia, radiotherapy and thermoradiotherapy on tumor microvascular permeability. Acta Pathol. Jpn. 1990, 40, 79-84.
26. Gerlowski, L.E.; Jain, R.K. Effect of hyperthermia on microvascular permeability to macromolecules in normal and tumor tissues. Int. J. Microcirc. Clin. Exp. 1985, 4, 363-372.
27. Jain, R.K. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 1987, 6, 559-593.
28. Temsamani, J.; Guinot, P. Antisense oligonucleotides: a new therapeutic approach. Biotechnol. Appl. Biochem. 1997, 26, 65-71.
29. Temsamani, J.; Vidal, P. The use of cell-penetrating peptides for drug delivery. Drug Discov. Today 2004, 9, 1012-1019.
30. Nori, A.; Kopecek, J. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv Drug Deliv. Rev. 2005, 57, 609-636.
31. Massodi, I.; Bidwell, G.L.; Raucher, D. Evaluation of cell penetrating peptides fused to elastin- like polypeptide for drug delivery. J. Control. Release 2005, 705, 396-408.
32. Massodi, I.; Raucher, D. A thermally responsive Tat-elastin-like polypeptide fusion protein induces membrane leakage, apoptosis, and cell death in human breast cancer cells. J. Drug Target 2007, 75, 611-622.
33. Vives, E.; Brodin, P.; Lebleu, B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 1997, 272, 16010-16017.
34. Meyer, D.E.; Shin, B.C.; Kong, G.A.; Dewhirst, M.W.; Chilkoti, A. Drug targeting using thermally responsive polymers and local hyperthermia. J. Control. Release 2001, 74, 213-224.
35. Bidwell, G.L.; Raucher, D. Application of thermally responsive polypeptides directed against c- Myc transcriptional function for cancer therapy. Mol. Cancer Ther. 2005, 4, 1076-1085.
36. Chilkoti, A.; Dreher, M.R.; Meyer, D.E. Design of thermally responsive, recombinant polypeptide carriers for targeted drug delivery. Adv. Drug Deliv. Rev. 2002, 54, 1093-1111.
37. Bidwell, G.L. Enhancing the Antiproliferative Effect of Topoisomerase II Inhibitors Using a Polypeptide Inhibitor of c-Myc. Biochem. Pharm. 2005, in press.
38. Bidwell, G.L.; Fokt, I.; Priebe, W.; Raucher, D. Development of Elastin-like Polypeptide for Thermally-targeted Delivery of Doxorubicin. Biochem. Pharmacol. 2006, In Press.
39. Hristova, K.; Dempsey, C. E.; White, S. H. Structure, location, and lipid perturbations of melittin at the membrane interface. Biophys. J. 2001, 80, 801-811.
40. Lehmann, J.; Retz, M.; Sidhu, S.S.; Suttmann, H.; Sell, M.; Paulsen, F.; Harder, J.; Unteregger, G.; Stockle, M. Antitumor activity of the antimicrobial peptide magainin II against bladder cancer cell lines. Eur. Urol. 2006, 50, 141-147.
41. Mori, S.; Watanabe, W.; Shigeta, S. A colorimetric LDH assay for the titration of infectivity and the evaluation of anti-viral activity against ortho- and paramyxoviruses. Tohoku J. Exp. Med. 1995, 777, 315-325.
42. Jurisic, V.; Spuzic, I.; Konjevic, G. A comparison of the NK cell cytotoxicity with effects of TNF-alpha against K-562 cells, determined by LDH release assay. Cancer Lett. 1999, 138, 67-72.
43. Do, T.N.; Rosal, R.V.; Drew, L.; Raffo, A.J.; Michl, J.; Pincus, M.R.; Friedman, F.K.; Petrylak, D.P.; Cassai, N.; Szmulewicz, J.; Sidhu, G.; Fine, R.L. Brandt-Rauf, P. W. Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site. 2000, 22, 1431-1444.
44. Kroemer, G.; Dallaporta, B.; Resche-Rigon, M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu. Rev. Physiol. 1998, 60, 619-642.
45. Zou, H.; Henzel, W.J.; Liu, X.; Lutschg, A.; Wang, X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997, 90, 405-413.
46. Meyer, D.E.; Chilkoti, A. Purification of Recombinant Proteins by Fusion with Thermally Responsive Polypeptides. Nat. Biotechnol. 1999, 77, 1112-1115.